LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Incidence Rate of Kaposi Sarcoma in HIV-Infected Patients on Antiretroviral Therapy in Southern Africa: A Prospective Multicohort Study.

Publication

Author(s):

Rohner E, Valeri F, Maskew M, Prozesky H, Rabie H, Garone D, Dickinson D, Chimbetete C, Lumano-Mulenga P, Sikazwe I, Wyss N, Clough-Gorr KM, Egger M, Chi BH, Bohlius J.

Pub Title:

Incidence Rate of Kaposi Sarcoma in HIV-Infected Patients on Antiretroviral Therapy in Southern Africa: A Prospective Multicohort Study.

Pub Date:

Dec 15 2014

Pub Region(s):

Southern Africa

Journal:

Title: 
JAIDS- Journal of Acquired Immune Deficiency Syndromes
Link: 
http://ovidsp.tx.ovid.com/sp-3.13.1a/ovidweb.cgi?QS2=434f4e1a73d37e8c3b61fcc465cfeaf247a5977e141ef492ab545b1d98fe9a297d213e7a02762675b14a2f9d36ec4e608c4807fe1a4603d408a8c7dd2172150f8d55ab8dc1745eaa741826c25fbfc9c73ed63747159a7ac6959c6f4de224ad2b9ed28091d8

PubMed: 25393941
Pub PDF: PDF icon 25393941.pdf

Abstract
BACKGROUND:
The risk of Kaposi sarcoma (KS) among HIV-infected persons on antiretroviral therapy (ART) is not well defined in resource-limited settings. We studied KS incidence rates and associated risk factors in children and adults on ART in Southern Africa.

METHODS: We included patient data of 6 ART programs in Botswana, South Africa, Zambia, and Zimbabwe. We estimated KS incidence rates in patients on ART measuring time from 30 days after ART initiation to KS diagnosis, last follow-up visit, or death. We assessed risk factors (age, sex, calendar year, WHO stage, tuberculosis, and CD4 counts) using Cox models.

FINDINGS: We analyzed data from 173,245 patients (61% female, 8% children aged <16 years) who started ART between 2004 and 2010. Five hundred and sixty-four incident cases were diagnosed during 343,927 person-years (pys). The overall KS incidence rate was 164/100,000 pys [95% confidence interval (CI): 151 to 178]. The incidence rate was highest 30-90 days after ART initiation (413/100,000 pys; 95% CI: 342 to 497) and declined thereafter [86/100,000 pys (95% CI: 71 to 105), >2 years after ART initiation]. Male sex [adjusted hazard ratio (HR): 1.34; 95% CI: 1.12 to 1.61], low current CD4 counts (≥500 versus <50 cells/μL, adjusted HR: 0.36; 95% CI: 0.23 to 0.55), and age (5-9 years versus 30-39 years, adjusted HR: 0.20; 95% CI: 0.05 to 0.79) were relevant risk factors for developing KS.

INTERPRETATION: Despite ART, KS risk in HIV-infected persons in Southern Africa remains high. Early HIV testing and maintaining high CD4 counts is needed to further reduce KS-related morbidity and mortality.

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Rohner E, Valeri F, Maskew M, Prozesky H, Rabie H, Garone D, Dickinson D, Chimbetete C, Lumano-Mulenga P, Sikazwe I, Wyss N, Clough-Gorr KM, Egger M, Chi BH, Bohlius J. Incidence Rate of Kaposi Sarcoma in HIV-Infected Patients on Antiretroviral Therapy in Southern Africa: A Prospective Multicohort Study. J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):547-54. doi: 10.1097/QAI.0000000000000360. PubMed PMID: 25393941; PubMed Central PMCID: PMC4231535.